Open AccessLipoteichoic acid from Bifidobacterium animalis subsp. lactis BPL1: a novel postbiotic that reduces fat deposition via IGF‐1 pathway
Author(s) -
Balaguer Ferran,
Enrique María,
Llopis Silvia,
Barrena Marta,
Navarro Verónica,
Álvarez Beatriz,
Chenoll Empar,
Ramón Daniel,
Tortajada Marta,
Martorell Patricia
Publication year - 2022
Publication title -
microbial biotechnology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.287
H-Index - 74
ISSN - 1751-7915
DOI - 10.1111/1751-7915.13769
Subject(s) - bifidobacterium animalis , lipoteichoic acid , probiotic , context (archaeology) , population , biology , caenorhabditis elegans , diabetes mellitus , obesity , strain (injury) , microbiology and biotechnology , bacteria , bifidobacterium , chemistry , biochemistry , medicine , staphylococcus aureus , endocrinology , gene , lactobacillus , genetics , paleontology , environmental health , anatomy
Summary Obesity and its related metabolic disorders, such as diabetes and cardiovascular disease, are major risk factors for morbidity and mortality in the world population. In this context, supplementation with the probiotic strain Bifidobacterium animalis subsp. lactis BPL1 (CECT8145) has been shown to ameliorate obesity biomarkers. Analyzing the basis of this observation and using the pre‐clinical model Caenorhabditis elegans, we have found that lipoteichoic acid (LTA) of BPL1 is responsible for its fat‐reducing properties and that this attribute is preserved under hyperglycaemic conditions. This fat‐reducing capacity of both BPL1 and LTA‐BPL1 is abolished under glucose restriction, as a result of changes in LTA chemical composition. Moreover, we have demonstrated that LTA exerts this function through the IGF‐1 pathway, as does BPL1 strain. These results open the possibility of using LTA as a novel postbiotic, whose beneficial properties can be applied therapeutically and/or preventively in metabolic syndrome and diabetes‐related disorders.